Esta página aún no está traducida al español y se muestra en inglés. Estamos trabajando en su traducción.

9 November 2026 · Actualizado November 2026 · 12 min read

Exosomes After Morpheus8 and RF Microneedling: How Practices Build the Protocol

Exosomes after Morpheus8 and RF microneedling: same visit or next day, how RF heat and channel closure set timing, what was studied, and what to record.

ExosomesRF MicroneedlingMorpheus8PotenzaSylfirm XChannel ClosurePractice DocumentationFDA Regulation
BB
Fuentes citadas

Every located human study of exosomes after Morpheus8-style RF microneedling applied the material in the same visit as the device pass, two of them stating that it went on immediately afterward, and none tested a next-day application [1, 2, 3]. A 2026 laboratory study put channel closure after RF microneedling within about 12 hours, which is consistent with the published protocols keeping the two steps together [8].

This guide sets out how RF heat changes the channels, what the studies with vesicle material reported, which handling steps shift on a device day, and what a practice file should record. Whether, when and how to combine any material with a device session is the practitioner’s decision, and ExaVeyra speaks here as a supplier.

Morpheus8, Potenza and Sylfirm X are trademarks of their respective owners. The systems are named because that is how practices search for them, and the rest of this guide says RF microneedling.

Same visit
when the located RF microneedling studies applied vesicle material, within the device session (Estupiñan 2025, Huang 2026, Yen 2026)
Within 12 h
channel closure after RF microneedling, measured by water loss on porcine skin (Lee WR 2026)
16
studies of facial vesicle use in a 2026 systematic review that rated GRADE certainty low or very low (Gaebe 2026)

Regulatory position

The FDA stated in its 2019 public safety notification, still posted on fda.gov as of 9 November 2026, that there are currently no FDA-approved exosome products [17]. The three RF microneedling systems named here were cleared under 21 CFR 878.4400 as electrosurgical devices [19], and the FDA’s microneedling page states that microneedling devices are not approved for delivering cosmetics, topical medications, drugs or blood products into the skin [18]. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats.

Understanding how RF heat changes the microneedle channel

RF microneedling delivers high-frequency current through fine needles, so each channel carries a zone of heated, coagulated tissue around it [9]. Wang and colleagues reported in 2024, in a porcine model, that power level and pulse duration significantly affected the amount of coagulation, that high-energy treatment produced tissue loss and necrosis, and that the tissue reaction was more pronounced in bipolar mode than in monopolar mode [9].

That thermal rim is the main difference from mechanical microneedling. Banzhaf and colleagues reported in a 2019 in vitro study, with channels made by microneedles or an ablative fractional laser, that the thickness of the coagulation zone around a channel changed the fluorescence of two small test molecules in the skin, with different patterns for hydrophilic and lipophilic molecules [10]. No located study has repeated this with RF channels or vesicle-sized particles, so the finding marks a question rather than an answer.

Mechanical needle channels give a useful benchmark. Gupta and colleagues measured skin resealing in human volunteers in 2011 and reported that unoccluded microneedle sites recovered barrier properties within about two hours, while occluded sites resealed over 3 to 40 hours depending on needle geometry [11].

Understanding channel closure after RF microneedling

Lee WR and colleagues compared fractional Er:YAG laser and RF microneedling on porcine skin in 2026 and reported, from transepidermal water-loss measurements, that channels closed within 12 hours after RF microneedling and within 36 hours after laser [8]. They also tested lipid nanocarriers of 76 and 81 nanometers, close to the size of small vesicles, and reported that these were distributed mainly into the channels and on into the surrounding dermis, and that the channels raised their delivery less than they raised delivery of the free drugs [8].

Intact skin is a firm barrier for particles of this size. Hsieh and colleagues labeled small vesicles with fluorescent nanodiamonds in 2026 and reported that most remained above a skin tissue model, with a measurable fraction entering the tissue layers and negligible passage through it [12].

Read together, the two studies are consistent with the published timing [8, 12]. The window in which a vesicle-sized particle meets an open channel after RF microneedling appears to be hours, and no located human study has measured how deep vesicles travel through RF channels.

Same session or next day: the published protocols keep both steps in one visit

Estupiñan, Ly and Goldberg applied topical exosomes and PRP to opposite halves of the face immediately after each of three RF microneedling sessions, according to the full text of their 2025 trial [1]. Huang and colleagues applied a plant-derived vesicle formulation immediately after needling RF in their 2026 pilot [3], and Yen and colleagues applied a topical vesicle preparation after RF microneedling on one side in their 2026 study [2].

TimingChannel state reported in the literatureLocated human studies
Same visit, right after the device passChannels open; closure within 12 h on porcine skin (Lee WR 2026)Estupiñan 2025; Huang 2026; Yen 2026 (interval not stated in the abstract)
Later the same dayChannels closing over the following hoursNone located
Next dayChannels closed in the porcine model; limited passage through a skin tissue model (Hsieh 2026)None located
Take-home product in the days afterBarrier recovering; surface contact onlyEstupiñan 2025 used a post-procedure exosome cream on the exosome side for 10 days

The table records what has been studied, and a practice may weigh other factors, such as pinpoint bleeding, the patient’s comfort and the device settings, when it sets its own sequence. Where a protocol departs from the published timing, the practice file is the place to note the reason.

Reviewing the RF microneedling studies with vesicle material

Estupiñan and colleagues ran an investigator-blinded, non-randomized, split-face non-inferiority trial in 15 adults on a Sylfirm X device, three sessions four weeks apart, at reported depths of 0.7 to 1.5 millimeters [1]. They reported that both halves improved equally in wrinkling, dyschromia, erythema and texture, with histological increases in collagen I and glycosaminoglycans and no significant difference between the exosome and PRP arms [1]. The full text states that the study was supported in part by a research grant from the exosome product manufacturer [1].

Yen, Huang and Lin reported a 60-participant split-face study in 2026 in which the side receiving RF microneedling plus a vesicle preparation showed a 3.32-point greater wrinkle-severity improvement at 12 weeks than the side receiving RF microneedling alone [2]. The authors cautioned that the unblinded design, the 12-week follow-up and the absence of histologic or molecular biomarkers require cautious interpretation [2].

Huang and colleagues followed six adults for six months and reported greater wrinkle reduction on the vesicle side at one and three months, with texture and pore responses that varied by skin phenotype [3]. Park GH and colleagues used mechanical microneedling with a saline-controlled side in 28 adults in 2023 and reported higher aesthetic improvement scores and instrument-measured gains on the exosome side [4].

StudyDevice and materialDesignnFollow-up
Estupiñan 2025RF microneedling (Sylfirm X); adipose MSC exosomes vs PRPInvestigator-blinded, non-randomized split-face non-inferiority156 months, with biopsies in 10
Yen 2026RF microneedling; topical vesicle preparation vs noneRandomized split-face, unblinded6012 weeks
Huang 2026Needling RF; plant-derived vesicle formulation vs noneSplit-face pilot, random side66 months
Park GH 2023Mechanical microneedling; adipose stem cell exosome solution vs salineRandomized split-face2812 weeks
NCT07849556RF microneedling; sponsor vesicle solution vs noneRandomized, masked, manufacturer-sponsored30Completed 2025; no located publication

One older trial no longer counts. A 2013 randomized split-face study of RF microneedling with stem cell conditioned medium was retracted by its journal [16], so a review or brochure that cites it overstates the evidence.

Understanding what the three device clearances cover

The FDA cleared each of the three systems through the 510(k) pathway under 21 CFR 878.4400, which identifies a device intended to remove tissue and control bleeding by use of high-frequency electrical current [19]. That classification covers the device and says nothing about a topical product applied afterward.

SystemExample clearance in the FDA 510(k) databaseRegulation and product code
Morpheus8 applicatorsK192695, December 201921 CFR 878.4400, GEI
PotenzaK192545, February 202021 CFR 878.4400, GEI
Sylfirm XK200185, April 202021 CFR 878.4400, GEI

The FDA’s microneedling page adds that the risks of combining microneedling devices with other products are not known, and the aesthetic microneedling identification at 21 CFR 878.4430 excludes devices intended for transdermal delivery of topical products such as cosmetics, drugs or biologics [18]. A practice file that records the clearance number for the exact system and applicator used keeps that distinction visible.

Handling steps that change on an RF microneedling day

Because the studies applied material within minutes of the device pass, preparation moves earlier in the visit. Görgens and colleagues reported in 2022 that plain phosphate-buffered saline severely reduced vesicle recovery within minutes when used as a diluent, while buffer with human albumin and trehalose preserved vesicles at minus 80 degrees Celsius and across several freeze-thaw cycles [15].

  • Storage and thaw: keep frozen material at the temperature the supplier states and follow the supplier’s thaw and reconstitution instructions, recording the time out of the freezer.
  • Diluent: use only the diluent the supplier specifies, since the choice changed vesicle recovery in the Görgens 2022 study [15].
  • Timing: record the minutes between reconstitution and application, and between the last device pass and application.
  • Split-face or split-area protocols: record which side received which material and which lot.
  • Surface contact: record that the material went on the skin surface, the area covered and the applicator used.
  • Settings: record mode, depth, power, pulse duration and passes for each area, since Wang 2024 linked power and pulse to the thermal zone [9].

The International Society for Extracellular Vesicles sets out reporting expectations for characterization in MISEV2023, including particle concentration, size, protein markers and morphology [14]. A certificate of analysis that maps to those headings lets a practice compare its lot with the material described in a published study.

Rating the certainty of the evidence

Gaebe and colleagues applied GRADE to 16 studies of vesicle-based facial rejuvenation with 503 participants in 2026. They reported that most studies found improvement in at least one skin-quality outcome and no serious adverse events, with risk of bias moderate to critical for most effectiveness outcomes and GRADE certainty low or very low [5].

Wang, Bajwa and Rivers mapped 17 human dermatology studies in a 2026 scoping review and reported improvement in 76 percent, with small samples and short follow-up limiting interpretation [6]. Knauer and colleagues reviewed 18 topical exosome studies and 20 commercial products in 2026 and reported that the products contained minimal information on isolation, processing or shelf life [7].

Skin type deserves its own line in the file. Dreifus and colleagues reviewed device use in Fitzpatrick types IV to VI in 2026 and reported that epidermal melanin competes as a chromophore, raising the risk of pigment change, and that large prospective trials in darker skin types are lacking [13].

Understanding what the evidence does not yet show

The RF microneedling literature with vesicle material is small and recent, and its gaps are specific enough to list. Each one is also a design choice the next study can improve on.

  • No located study compares same-visit application with next-day application after RF microneedling.
  • No located human study has measured how far vesicles travel through RF channels; the closure figure comes from porcine skin [8].
  • The located RF studies enrolled 6, 15 and 60 participants, and the largest was unblinded [1, 2, 3].
  • Split-face designs share one circulation, so an effect on one side may in principle reach the other.
  • Materials differ by source, isolation and concentration, and commercial products carry little information on isolation and processing [7, 14].
  • Follow-up runs from 12 weeks to 6 months, and darker skin types are underrepresented.
  • A manufacturer-sponsored RF microneedling study (NCT07849556) completed in 2025 and, as of 9 November 2026, had no posted results or located publication, so the published record may lean positive [20].
  • None of the located studies names a Morpheus8 or Potenza system; the device-specific evidence covers Sylfirm X only.

Documenting an RF microneedling session with exosome material

A practice that records the same fields the published studies report can compare its own outcomes with the literature and answer an auditor’s or a patient’s questions from one file.

  • The device by system, applicator and 510(k) number, with mode, depth, power, pulse duration and passes per area
  • The interval from the last device pass to surface application, in minutes
  • The material by name and class, its lot number, expiry, certificate of analysis and characterization panel
  • The cold-chain record from receipt to use, the diluent, and the time between reconstitution and application
  • Fitzpatrick type and pigment history, with the settings chosen for that skin type
  • Recovery observations such as erythema, edema, crusting and patient-reported downtime
  • Any adverse event with the lot number, reported to the FDA through MedWatch [17]

Questions worth putting to any supplier follow from the same list: whether each vial carries a lot number, whether a certificate of analysis is generated for every lot and can be supplied on request, which characterization methods the panel uses, how the material ships and at what temperature, and which diluent the instructions specify.

RF microneedling with vesicle material is an active research area, and the next round of larger, blinded and registered studies will sharpen the timing question. ExaVeyra supplies exosome material to licensed practitioners, described by its available formats; it ships frozen from the manufacturing facility with the lot number on each vial, and the certificate of analysis, characterization panel and cold-chain records for every lot can be requested, so the practice file starts complete. Practices that document each session carefully are well placed to read that new evidence against their own records.

Practices with a question about a product, a certificate or a documentation field are welcome to ask the scientific team directly, and anyone can apply for a free account without an NPI; NPI verification then unlocks the practitioner portal, exclusive resources and pricing, so a practice building an RF microneedling protocol can apply for a verified account today.

Aviso Educativo: This article is for educational purposes only and does not constitute medical or legal advice. It does not identify any material, compound, device setting or protocol as safe, effective or appropriate for any patient, and it is not intended to diagnose, treat, cure, or prevent any disease. Questions about a treatment belong with the reader’s own licensed provider. Exosome material is supplied for topical aesthetic use by licensed practitioners. No exosome product is FDA-approved for any use, and ExaVeyra Sciences makes no statement about administration, route, or outcome. Compounded medications are not FDA-approved. They are prepared by a 503A compounding pharmacy licensed by the Texas State Board of Pharmacy for an individual patient against that patient’s prescription, and are available to NPI-verified licensed practitioners only, in the states where the pharmacy is licensed. Product, device and brand names mentioned are trademarks of their respective owners and are used only to identify the products discussed. Their mention is not an endorsement, and those owners have not reviewed or endorsed this article. ExaVeyra Sciences is a supplier and takes no part in any diagnosis, treatment decision, or plan of care. Findings described are attributed to the peer-reviewed literature, trial registries and agencies cited. The content of these guides is provided for general informational purposes only. It does not constitute legal, medical, or regulatory advice, and does not establish that any particular product or practice is compliant. Regulatory requirements vary by state and depend on the circumstances of each practice. Each practitioner should consult their own legal counsel and the applicable state licensing boards before acting on anything stated here.

Referencias

  1. 1.Estupiñan B, Ly K, Goldberg DJ. Adipose Mesenchymal Stem Cell-Derived Exosomes Versus Platelet-Rich Plasma Treatment for Photoaged Facial Skin: An Investigator-Blinded, Split-Face, Non-Inferiority Trial. J Cosmet Dermatol. 2025;24(5):e70208. PMID 40414798. PMC12104007. doi:10.1111/jocd.70208Investigator-blinded, split-face, non-inferiority trial; three full-face RF microneedling sessions four weeks apart on a Sylfirm X device, with topical adipose MSC exosomes on one half of the face and PRP on the other, both applied immediately after the device pass; adults aged 44 to 68 with mild to moderate facial photoaging (USA); n = 15 enrolled, 14 completed. Carries in this article: the only located head-to-head comparison of exosomes and PRP after RF microneedling, the same-session timing, the reported settings (continuous wave mode, depth 0.7 to 1.5 mm), punch biopsies in the first 10 participants, and the 10-day post-procedure exosome cream on the exosome side. The full text describes the design as non-randomized. Disclosure: supported in part by a research grant to the investigators’ practice from the exosome product manufacturer, which also distributes the device (full text); the authors declared no conflicts of interest.
  2. 2.Yen C, Huang H, Lin C. Radiofrequency Microneedling Combined With Topical Extracellular Vesicle Preparation for Facial Rejuvenation: A Randomized Split-Face Controlled Study. J Craniofac Surg. 2026. Published online ahead of print. PMID 42635327. doi:10.1097/SCS.0000000000013266Randomized split-face controlled study, unblinded, assessed at baseline, week 4 and week 12; adults (Taiwan), mean age 43.6, 83 percent women; n = 60. Carries in this article: the largest located split-face study of RF microneedling with a topical vesicle preparation; a paired wrinkle-score difference of 3.32 points (95% CI 2.55 to 4.08) at week 12 and the authors’ own caveats on blinding, follow-up and missing biomarkers. Disclosure: the authors reported no conflicts of interest.
  3. 3.Huang PP, Chih PL, OuYang SY. Preliminary Insights From a Split-Face Study on Skin Quality Changes After Needling Radiofrequency With or Without a Plant-Derived Exosome-Based Formulation Over 6 Months. Aesthet Surg J. 2026;46:S62-S72. PMID 41800727. doi:10.1093/asj/sjaf253Prospective split-face pilot with random side assignment, follow-up at 1, 3 and 6 months by standardized photography and 3D imaging; Asian adults, Fitzpatrick III to IV; n = 6. Carries in this article: a rose stem cell-derived vesicle formulation applied immediately after needling RF; wrinkle differences at 1 and 3 months and texture and pore responses that varied by skin phenotype. Disclosure: published in an Aesthetic Surgery Journal supplement on exosomes; the PubMed record carries no funding or COI statement.
  4. 4.Park GH, Kwon HH, Seok J, Yang SH, Lee J, Park BC, et al. Efficacy of combined treatment with human adipose tissue stem cell-derived exosome-containing solution and microneedling for facial skin aging: A 12-week prospective, randomized, split-face study. J Cosmet Dermatol. 2023;22(12):3418-3426. PMID 37377400. doi:10.1111/jocd.15872Prospective, randomized, split-face comparative study, three sessions three weeks apart, followed for 6 weeks after the last session, saline on the control side; adults (Korea); n = 28. Carries in this article: the saline-controlled mechanical microneedling comparison, the nearest controlled design to the RF studies, with instrument endpoints and histology. Disclosure: National Research Foundation of Korea grants listed in the PubMed record; no COI statement in the record.
  5. 5.Gaebe K, Lowe K, Bosnalie D, Khoury S, Villemure Poliquin N, Nichols A. Effectiveness and Safety of Extracellular Vesicle-Based Therapies for Nonsurgical Facial Rejuvenation: A Systematic Review. Facial Plast Surg Aesthet Med. 2026. Published online ahead of print. PMID 42487416. doi:10.1177/26893614261457879PRISMA systematic review with risk-of-bias tools and GRADE, searches January 2000 to June 2025; 16 studies, 503 participants. Carries in this article: the certainty rating for facial vesicle studies; most studies reported improvement in at least one skin-quality outcome and no serious adverse events, risk of bias was moderate to critical, and GRADE certainty was low or very low. Disclosure: academic authors (Canada); no COI statement in the PubMed record.
  6. 6.Wang OJE, Bajwa BB, Rivers JK. Exosome-Based Therapies in Dermatology: A Scoping Review. J Drugs Dermatol. 2026;25(4):368-376. PMID 41931695. doi:10.36849/jdd.9610Scoping review (PRISMA-ScR) including US and EU trial registries; 17 human studies from 2020 to 2025. Carries in this article: delivery routes reported in the human literature (topical application, microneedling, fractional CO2 and injection), 76 percent of studies recording improvement, and the limitations of small samples and short follow-up. Disclosure: no COI statement in the PubMed record.
  7. 7.Knauer G, Chang A, Gupta A, Brownstone N, Mejia N, Bauman S, et al. Clinical Evidence and Commercial Landscape of Topical Exosomes for Skin Rejuvenation: A Scoping Review. Aesthet Surg J. 2026;46(11):NP148-NP157. PMID 42411735. doi:10.1093/asj/sjag141Scoping review with librarian-reviewed search (2,394 records screened) plus a survey of the first 20 commercial products returned by a shopping search; 18 human studies, 10 of them pairing exosomes with a delivery modality. Carries in this article: the commercial products carried minimal information on isolation, processing or shelf life, the reason this guide asks practices to document lot and characterization data. Disclosure: academic authors (USA); no COI statement in the PubMed record.
  8. 8.Lee WR, Alalaiwe A, Tsai MT, Hu S, Chang FH, Chien MY, et al. Fractional microporation-guided delivery of nanoencapsulated drugs for enhanced cutaneous and follicular absorption: a comparison of ablative laser and radiofrequency microneedling. Drug Deliv Transl Res. 2026;16(1):248-267. PMID 40439860. doi:10.1007/s13346-025-01885-xPreclinical study (porcine skin permeation testing plus a mouse model) comparing fractional Er:YAG laser and RF microneedling at 0.5 and 1.0 mm depth. Carries in this article: transepidermal water-loss measurements indicating channel closure within 12 hours after RF microneedling and within 36 hours after laser, and lipid nanocarriers of 76 and 81 nm, close to small-vesicle size, that were distributed mainly into the channels and on into the surrounding dermis, with a smaller delivery gain from microporation than the free drugs. Disclosure: the authors declared no competing interests.
  9. 9.Wang H, Hamblin MR, Zhang Y, Xu Y, Wen X. Histological evaluation of monopolar and bipolar radiofrequency microneedling treatment in a porcine model. Lasers Surg Med. 2024;56(3):288-297. PMID 38334177. doi:10.1002/lsm.23768Preclinical histology in porcine dorsal skin, monopolar against bipolar RF microneedling, follow-up at 0, 14, 30 and 90 days. Carries in this article: coagulation amount significantly affected by power level and pulse duration, tissue loss and necrosis at high energy, and a stronger tissue reaction in bipolar mode, the thermal zone that distinguishes RF microneedling from mechanical needling. Disclosure: no COI statement in the PubMed record.
  10. 10.Banzhaf CA, Ortner VK, Philipsen PA, Haedersdal M. The ablative fractional coagulation zone influences skin fluorescence intensities of topically applied test molecules-An in vitro study with fluorescence microscopy and fluorescence confocal microscopy. Lasers Surg Med. 2019;51(1):68-78. PMID 30584842. doi:10.1002/lsm.23034In vitro skin study with 700 µm channels made by microneedles or ablative fractional laser, coagulation zones of 0, 20 and 80 µm, imaged after 4 hours of incubation. Carries in this article: the thickness of a thermal coagulation zone changed skin fluorescence intensities of two small test molecules, differently for hydrophilic and lipophilic molecules; a laser model with no RF or vesicle arm. Disclosure: no COI statement in the PubMed record; academic authors (Copenhagen).
  11. 11.Gupta J, Gill HS, Andrews SN, Prausnitz MR. Kinetics of skin resealing after insertion of microneedles in human subjects. J Control Release. 2011;154(2):148-55. PMID 21640148. PMC3164267. doi:10.1016/j.jconrel.2011.05.021Human in vivo study using electrical impedance spectroscopy across microneedle geometries, with and without occlusion. Carries in this article: unoccluded microneedle sites recovered barrier properties within about 2 hours, while occluded sites resealed over 3 to 40 hours, the mechanical-needling benchmark against which the RF closure figure is read. Disclosure: NIH and other grant support listed in the PubMed record; academic authors.
  12. 12.Hsieh MW, Su YS, Chen LY, Zhang ZX, Su LJ, Lin HH, et al. Novel Approach for Assessment of Dermal Absorption of Extracellular Vesicle Products Using Immunoaffinity Fluorescent Nanodiamonds. Skin Pharmacol Physiol. 2026;39(1):35-46. PMID 41587148. doi:10.1159/000550612In vitro permeation study with fluorescent nanodiamond-labeled small EVs (62.5 to 141.1 nm) on a skin tissue model. Carries in this article: labeled vesicles remained predominantly in the supernatant above the tissue, with a measurable fraction entering the tissue layers and negligible passage into the filtrate, a contrast with the open-channel timing of the published protocols. Disclosure: no COI statement in the PubMed record; several authors are affiliated with companies that develop the nanodiamond label.
  13. 13.Dreifus EM, Burke OM, Alexis AF, Dover JS, Eber AE. Laser and energy-based device use in skin of color: A clinical review of safety, efficacy, and best practices. J Am Acad Dermatol. 2026. Published online ahead of print. PMID 42660430. doi:10.1016/j.jaad.2026.08.077Clinical narrative review of device use in Fitzpatrick IV to VI. Carries in this article: epidermal melanin as a competing chromophore, the risk of post-inflammatory pigment change, conservative settings, and the lack of large prospective trials in darker skin types. Disclosure: three authors (Alexis, Dover, Eber) disclosed grants, equipment, advisory or speaking relationships with energy-based device companies, including an RF microneedling device maker.
  14. 14.Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al; MISEV Consortium; Théry C, Witwer KW. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J Extracell Vesicles. 2024;13(2):e12404. PMID 38326288. PMC10850029. doi:10.1002/jev2.12404International Society for Extracellular Vesicles reporting guideline, compiled with ISEV task forces and more than 1,000 researchers. Carries in this article: the reference headings for nomenclature, separation and characterization (size, concentration, markers, morphology) that a certificate of analysis can map to. Disclosure: many consortium authors list EV company affiliations, declared in full in the article.
  15. 15.Görgens A, Corso G, Hagey DW, Jawad Wiklander R, Gustafsson MO, Felldin U, et al. Identification of storage conditions stabilizing extracellular vesicles preparations. J Extracell Vesicles. 2022;11(6):e12238. PMID 35716060. PMC9206228. doi:10.1002/jev2.12238In vitro stability study up to 2 years across buffers and temperatures, EVs from several cell sources. Carries in this article: plain PBS reduced vesicle recovery within days in storage and within minutes as a diluent, while PBS with human albumin and trehalose preserved vesicles at minus 80 degrees and across freeze-thaw cycles; the basis for recording the diluent and preparation time. Disclosure: several authors list affiliation with an EV therapeutics company.
  16. 16.Statement of Retraction: Skin rejuvenation by microneedle fractional radiofrequency and a human stem cell conditioned medium in Asian skin: a randomized controlled investigator blinded split-face study. J Cosmet Laser Ther. 2020;22(4-5):215. PMID 33739221. doi:10.1080/14764172.2020.1853339Publisher retraction notice for a randomized split-face study of RF microneedling with conditioned medium, originally published in 2013. Carries in this article: an early RF microneedling plus secretome trial has been withdrawn from the record, so older reviews and marketing that cite it overstate the evidence.
  17. 17.U.S. Food and Drug Administration. Public Safety Notification on Exosome Products. December 6, 2019 (content current as of 12/06/2019; verified 9 November 2026). https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/public-safety-notification-exosome-productsAgency safety notification (CBER). Carries in this article: the agency statement that there are currently no FDA-approved exosome products, that exosomes used to treat diseases and conditions in humans are regulated as drugs and biological products, and the MedWatch route for adverse event reports.
  18. 18.U.S. Food and Drug Administration. Microneedling Devices. Content current as of 10/15/2025; verified 9 November 2026. https://www.fda.gov/medical-devices/aesthetic-cosmetic-devices/microneedling-devices. With 21 CFR 878.4430, Microneedling device for aesthetic use (Class II; the identification excludes devices intended for transdermal delivery of topical products). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=878.4430Agency device information page and federal regulation (CDRH). Carries in this article: the page states that microneedling devices are not approved for delivery of cosmetics, topical medications, drugs or blood products into the skin, and that the risks of combining the devices with other products are not known; the aesthetic microneedling identification excludes transdermal delivery.
  19. 19.U.S. Food and Drug Administration. 21 CFR 878.4400, Electrosurgical cutting and coagulation device and accessories (Class II); text verified on eCFR 9 November 2026 (eCFR up to date as of 5 November 2026). https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=878.4400. 510(k) records, product code GEI: K192695, Morpheus8 (Fractora) Applicators, decision December 27, 2019, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K192695; K192545, Potenza, decision February 20, 2020, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K192545; K200185, SYLFIRM X, decision April 22, 2020, https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K200185Federal regulation and three 510(k) records (CDRH), cross-checked against the openFDA 510(k) database on 9 November 2026, which also lists later clearances for each system. Carries in this article: the three named RF microneedling systems were cleared as electrosurgical devices intended to remove tissue and control bleeding by high-frequency current; no clearance covers delivering a topical product.
  20. 20.ClinicalTrials.gov. NCT07849556: industry-sponsored clinical evaluation of a topical vesicle product with facial radiofrequency microneedling (the official title names the sponsor product). Completed June 18, 2025; record last updated September 30, 2026; no results posted. https://clinicaltrials.gov/study/NCT07849556Registry record, status verified 9 November 2026; randomized, parallel, masked to participant and outcomes assessor, all participants receiving RF microneedling with or without the sponsor’s vesicle solution; 30 participants enrolled (actual). Carries in this article: a completed RF microneedling study with no located publication, a reminder that the published record may lean positive. Disclosure: manufacturer-sponsored.

Pregunte a su profesional cómo se analizan sus exosomas

El análisis de laboratorio muestra qué contiene un lote: recuento de partículas, marcadores vesiculares, esterilidad y cómo se almacenó el material. Una práctica que se abastece con cuidado puede responder con los registros de su proveedor.

Preguntas frecuentes

Can you use exosomes after Morpheus8?
Whether to apply any material after an RF microneedling session is the practitioner’s decision, and the published studies show how it has been done. Estupiñan and colleagues applied topical exosomes immediately after each of three RF microneedling sessions in a 2025 split-face trial of 15 adults [1], and Yen and colleagues paired RF microneedling with a vesicle preparation in 60 adults in 2026 [2]. No located study names the Morpheus8 system itself, which the FDA cleared under 21 CFR 878.4400 (K192695), a clearance that does not cover a topical product [19].
Morpheus8 with exosomes: same session or next day?
Every located study applied the material in the same visit as the device pass, and none tested a next-day application [1, 2, 3]. Lee WR and colleagues reported in 2026 that RF microneedling channels closed within 12 hours on porcine skin [8], and Hsieh and colleagues reported in 2026 that labeled small vesicles stayed mainly above a skin tissue model without channels, with limited passage [12].
Have exosomes after RF microneedling been studied?
Yes, in small recent studies. Estupiñan, Ly and Goldberg reported in 2025 that topical exosomes and PRP after RF microneedling improved facial skin equally in 15 adults [1], Yen and colleagues reported a wrinkle-score difference favoring the vesicle side in 60 adults in 2026 [2], and Gaebe and colleagues rated the certainty of facial vesicle evidence as low or very low in a 2026 systematic review [5].
Is there research on an exosome with Potenza?
No located study names the Potenza system with vesicle material. Potenza was cleared as an electrosurgical device under 21 CFR 878.4400 (K192545) [19], and the nearest evidence is the RF microneedling literature, including Estupiñan and colleagues in 2025 and Yen and colleagues in 2026 [1, 2].
What has been studied on exosomes after Sylfirm?
Estupiñan, Ly and Goldberg used a Sylfirm X device, according to the full text of their 2025 investigator-blinded split-face trial, applying adipose MSC exosomes to one half of the face and PRP to the other immediately after each of three sessions [1]. They reported equal improvement on both halves and histological increases in collagen I and glycosaminoglycans, with no significant difference between arms [1]. Sylfirm X was cleared under 21 CFR 878.4400 (K200185) [19].
What does RF microneedling with exosomes cost?
None of the cited studies or reviews reports a price, so this guide gives no figure. A practice sets its own fee, and the inputs it can document are the device session, the exosome material in its available format and the time added to the visit; Knauer and colleagues surveyed 20 commercial exosome products in 2026 and reported minimal information on isolation, processing or shelf life [7], which is worth checking before comparing prices.
Is Morpheus8 plus exosomes FDA-approved?
The FDA stated in 2019 that there are currently no FDA-approved exosome products, and that notification remained posted as of 9 November 2026 [17]. The Morpheus8 applicators were cleared under 21 CFR 878.4400 as an electrosurgical device [19], and the FDA’s microneedling page states that microneedling devices are not approved for delivering topical products into the skin and that the risks of combining them with other products are not known [18].
What should a practice document for Morpheus8 plus exosomes?
The device system, applicator and 510(k) number with mode, depth, power and passes; the minutes from the last pass to application; the material’s lot number, certificate of analysis and characterization panel; the cold-chain record and diluent; and the patient’s skin type. Görgens and colleagues reported in 2022 that the diluent changed vesicle recovery [15], and MISEV2023 sets out the characterization expectations a certificate can map to [14].

ExaBlog Semanal para prácticas con licencia

Un correo por semana para prácticas con licencia: nuevas revisiones de investigación, guías prácticas y actualizaciones regulatorias de ExaBlog, cada artículo con sus fuentes.

Le escribimos en inglés salvo que marque esta casilla.

Sin spam. Cancele su suscripción en cualquier momento.